Selected research
Industry Growth & Trends
Global Progressive Supranuclear Palsy Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Progressive Supranuclear Palsy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Progressive Supranuclear Palsy is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Progressive Supranuclear Palsy is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Progressive Supranuclear Palsy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Progressive Supranuclear Palsy market include Novartis AG, Merck & Co., Inc., GlaxoSmithKline plc, Biogen Inc., Bristol Myers Squibb (BMS), AbbVie Inc., Acorda Therapeutics Inc., Teva Pharmaceutical Industries Ltd. and Cortice Biosciences, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Progressive Supranuclear Palsy market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Progressive Supranuclear Palsy market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Progressive Supranuclear Palsy market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Progressive Supranuclear Palsy.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Progressive Supranuclear Palsy market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Progressive Supranuclear Palsy Market by Company
Novartis AG
Merck & Co., Inc.
GlaxoSmithKline plc
Biogen Inc.
Bristol Myers Squibb (BMS)
AbbVie Inc.
Acorda Therapeutics Inc.
Teva Pharmaceutical Industries Ltd.
Cortice Biosciences, Inc.
Aton Pharma, Inc.
AlzProtect SAS
AB Science
Progressive Supranuclear Palsy Segment by Type
Late Stage
Clinical Trial
Early Stage
Others
Progressive Supranuclear Palsy Segment by Application
Clinics
Hospitals
Research Institutes
Others
Progressive Supranuclear Palsy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Progressive Supranuclear Palsy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Progressive Supranuclear Palsy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Progressive Supranuclear Palsy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Progressive Supranuclear Palsy companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Late Stage
- Clinical Trial
- Early Stage
- Others
Applications
- Clinics
- Hospitals
- Research Institutes
- Others
Companies covered
- Novartis AG
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Biogen Inc.
- Bristol Myers Squibb (BMS)
- AbbVie Inc.
- Acorda Therapeutics Inc.
- Teva Pharmaceutical Industries Ltd.
- Cortice Biosciences, Inc.
- Aton Pharma, Inc.
- AlzProtect SAS
- AB Science
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Progressive Supranuclear Palsy Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Progressive Supranuclear Palsy Market Size by Region (2021-2032)
- 1.4.1 Global Progressive Supranuclear Palsy Market Size by Region (2021-2026)
- 1.4.2 Global Progressive Supranuclear Palsy Market Size by Region (2027-2032)
- 1.5 Key Regions Progressive Supranuclear Palsy Market Size (2021-2032)
- 1.5.1 North America Progressive Supranuclear Palsy Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Progressive Supranuclear Palsy Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Progressive Supranuclear Palsy Market Size Growth Rate (2021-2032)
- 1.5.4 South America Progressive Supranuclear Palsy Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Progressive Supranuclear Palsy Market Size Growth Rate (2021-2032)
2 Progressive Supranuclear Palsy Market by Type
- 2.1 Type Introduction
- 2.1.1 Late Stage
- 2.1.2 Clinical Trial
- 2.1.3 Early Stage
- 2.1.4 Others
- 2.2 Global Progressive Supranuclear Palsy Market Size by Type
- 2.2.1 Global Progressive Supranuclear Palsy Market Size Overview by Type (2021-2032)
- 2.2.2 Global Progressive Supranuclear Palsy Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Progressive Supranuclear Palsy Market Size Forecasted by Type (2027-2032)
- 2.3 Global Progressive Supranuclear Palsy Market Size by Regions
- 2.3.1 North America Progressive Supranuclear Palsy Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Progressive Supranuclear Palsy Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Progressive Supranuclear Palsy Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Progressive Supranuclear Palsy Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Progressive Supranuclear Palsy Market Size Breakdown by Type (2021-2026)
3 Progressive Supranuclear Palsy Market by Application
- 3.1 Type Introduction
- 3.1.1 Clinics
- 3.1.2 Hospitals
- 3.1.3 Research Institutes
- 3.1.4 Others
- 3.2 Global Progressive Supranuclear Palsy Market Size by Application
- 3.2.1 Global Progressive Supranuclear Palsy Market Size Overview by Application (2021-2032)
- 3.2.2 Global Progressive Supranuclear Palsy Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Progressive Supranuclear Palsy Market Size Forecasted by Application (2027-2032)
- 3.3 Global Progressive Supranuclear Palsy Market Size by Regions
- 3.3.1 North America Progressive Supranuclear Palsy Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Progressive Supranuclear Palsy Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Progressive Supranuclear Palsy Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Progressive Supranuclear Palsy Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Progressive Supranuclear Palsy Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Progressive Supranuclear Palsy Industry Trends
- 4.2 Progressive Supranuclear Palsy Industry Drivers
- 4.3 Progressive Supranuclear Palsy Industry Opportunities and Challenges
- 4.4 Progressive Supranuclear Palsy Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Progressive Supranuclear Palsy Revenue (2021-2026)
- 5.2 Global Progressive Supranuclear Palsy Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Progressive Supranuclear Palsy Key Company Headquarters & Area Served
- 5.4 Global Progressive Supranuclear Palsy Company, Product Type & Application
- 5.5 Global Progressive Supranuclear Palsy Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Progressive Supranuclear Palsy Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Progressive Supranuclear Palsy Players Market Share by Revenue in 2025
- 5.6.3 2025 Progressive Supranuclear Palsy Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Novartis AG
- 6.1.1 Novartis AG Company Information
- 6.1.2 Novartis AG Business Overview
- 6.1.3 Novartis AG Progressive Supranuclear Palsy Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Novartis AG Progressive Supranuclear Palsy Product Portfolio
- 6.1.5 Novartis AG Recent Developments
- 6.2 Merck & Co., Inc.
- 6.2.1 Merck & Co., Inc. Company Information
- 6.2.2 Merck & Co., Inc. Business Overview
- 6.2.3 Merck & Co., Inc. Progressive Supranuclear Palsy Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Merck & Co., Inc. Progressive Supranuclear Palsy Product Portfolio
- 6.2.5 Merck & Co., Inc. Recent Developments
- 6.3 GlaxoSmithKline plc
- 6.3.1 GlaxoSmithKline plc Company Information
- 6.3.2 GlaxoSmithKline plc Business Overview
- 6.3.3 GlaxoSmithKline plc Progressive Supranuclear Palsy Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 GlaxoSmithKline plc Progressive Supranuclear Palsy Product Portfolio
- 6.3.5 GlaxoSmithKline plc Recent Developments
- 6.4 Biogen Inc.
- 6.4.1 Biogen Inc. Company Information
- 6.4.2 Biogen Inc. Business Overview
- 6.4.3 Biogen Inc. Progressive Supranuclear Palsy Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Biogen Inc. Progressive Supranuclear Palsy Product Portfolio
- 6.4.5 Biogen Inc. Recent Developments
- 6.5 Bristol Myers Squibb (BMS)
- 6.5.1 Bristol Myers Squibb (BMS) Company Information
- 6.5.2 Bristol Myers Squibb (BMS) Business Overview
- 6.5.3 Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Product Portfolio
- 6.5.5 Bristol Myers Squibb (BMS) Recent Developments
- 6.6 AbbVie Inc.
- 6.6.1 AbbVie Inc. Company Information
- 6.6.2 AbbVie Inc. Business Overview
- 6.6.3 AbbVie Inc. Progressive Supranuclear Palsy Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 AbbVie Inc. Progressive Supranuclear Palsy Product Portfolio
- 6.6.5 AbbVie Inc. Recent Developments
- 6.7 Acorda Therapeutics Inc.
- 6.7.1 Acorda Therapeutics Inc. Company Information
- 6.7.2 Acorda Therapeutics Inc. Business Overview
- 6.7.3 Acorda Therapeutics Inc. Progressive Supranuclear Palsy Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Acorda Therapeutics Inc. Progressive Supranuclear Palsy Product Portfolio
- 6.7.5 Acorda Therapeutics Inc. Recent Developments
- 6.8 Teva Pharmaceutical Industries Ltd.
- 6.8.1 Teva Pharmaceutical Industries Ltd. Company Information
- 6.8.2 Teva Pharmaceutical Industries Ltd. Business Overview
- 6.8.3 Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Product Portfolio
- 6.8.5 Teva Pharmaceutical Industries Ltd. Recent Developments
- 6.9 Cortice Biosciences, Inc.
- 6.9.1 Cortice Biosciences, Inc. Company Information
- 6.9.2 Cortice Biosciences, Inc. Business Overview
- 6.9.3 Cortice Biosciences, Inc. Progressive Supranuclear Palsy Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Cortice Biosciences, Inc. Progressive Supranuclear Palsy Product Portfolio
- 6.9.5 Cortice Biosciences, Inc. Recent Developments
- 6.10 Aton Pharma, Inc.
- 6.10.1 Aton Pharma, Inc. Company Information
- 6.10.2 Aton Pharma, Inc. Business Overview
- 6.10.3 Aton Pharma, Inc. Progressive Supranuclear Palsy Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Aton Pharma, Inc. Progressive Supranuclear Palsy Product Portfolio
- 6.10.5 Aton Pharma, Inc. Recent Developments
- 6.11 AlzProtect SAS
- 6.11.1 AlzProtect SAS Company Information
- 6.11.2 AlzProtect SAS Business Overview
- 6.11.3 AlzProtect SAS Progressive Supranuclear Palsy Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 AlzProtect SAS Progressive Supranuclear Palsy Product Portfolio
- 6.11.5 AlzProtect SAS Recent Developments
- 6.12 AB Science
- 6.12.1 AB Science Company Information
- 6.12.2 AB Science Business Overview
- 6.12.3 AB Science Progressive Supranuclear Palsy Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 AB Science Progressive Supranuclear Palsy Product Portfolio
- 6.12.5 AB Science Recent Developments
7 North America
- 7.1 North America Progressive Supranuclear Palsy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Progressive Supranuclear Palsy Market Size by Country (2021-2026)
- 7.3 North America Progressive Supranuclear Palsy Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Progressive Supranuclear Palsy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Progressive Supranuclear Palsy Market Size by Country (2021-2026)
- 8.3 Europe Progressive Supranuclear Palsy Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Progressive Supranuclear Palsy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Progressive Supranuclear Palsy Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Progressive Supranuclear Palsy Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Progressive Supranuclear Palsy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Progressive Supranuclear Palsy Market Size by Country (2021-2026)
- 10.3 South America Progressive Supranuclear Palsy Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Progressive Supranuclear Palsy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Progressive Supranuclear Palsy Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Progressive Supranuclear Palsy Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst